Study to Measure Impact of ProstaScint Imaging in Prostate Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 7
Volume 11
Issue 7

PRINCETON, New Jersey-Cytogen Corporation’s ProstaScint (capromab pendetide) is being evaluated in a phase I/II clinical study for its utility in helping guide intensity modulated radiation therapy (IMRT) for prostate cancer.

PRINCETON, New Jersey—Cytogen Corporation’s ProstaScint (capromabpendetide) is being evaluated in a phase I/II clinical study for its utility inhelping guide intensity modulated radiation therapy (IMRT) for prostate cancer. 

ProstaScint is a radiolabeled monoclonal antibody that targets prostate specificmembrane antigen. In the study, the specific areas of greatest tumor burdenwithin the prostate, identified by the ProstaScint image, will receive boosteddoses of radiation via IMRT.

Articles in this issue
Translational Research, Early Clinical Trials Support Xeloda/RT in GI Cancers
Capecitabine Research Points to New Combinations for Metastatic Breast Cancer
Good Activity for Capecitabine Confirmed in European Study
European Data Support Benefit of Capecitabine/Irinotecan Regimen in Advanced Colorectal Cancer Patients
Single-Agent Capecitabine May Benefit Elderly Colorectal Cancer Patients
Single-Agent Sequential Rx May Be Reasonable for Metastatic Breast Cancer
Intermittent R115777 Equally Effective but Better Tolerated in Breast Cancer Patients
Carboplatin/Vinorelbine/Capecitabine Active in Pretreated Metastatic Breast Cancer
Longer Survival With FOLFOX4 in Metastatic Colorectal Cancer Patients
Capecitabine/Vinorelbine Effective in Heavily Pretreated Patients
Oral Regimen of UFT/Leucovorin and Etoposide Shows Promising Results
Docetaxel/Capecitabine Bests Single-Agent Docetaxel in Metastatic Breast Cancer
COX-2 Inhibitor May Boost Capecitabine Response
Celecoxib Added to IFL Reduces Toxicity in Patients With Metastatic Colorectal Cancer
Irinotecan Every 2 Weeks With Capecitabine Is Well Tolerated

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.

Chemoradiation Prolongs OS, Maintains QOL in Advanced Gallbladder Cancers

Roman Fabbricatore
April 24th 2025
Article

Chemoradiotherapy resulted in lower incidence of local progression, prompting an evaluation of resectability in patients with advanced gallbladder cancers.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Rad Onc First to Dose 177Lu in US, Notes Enormity of Recent mCRPC Approval

Ariana Pelosci
April 17th 2025
Article

After the recent approval of 177Lu in PSMA+/mCPRCP prior to chemotherapy, Steven Finkelstein, MD, DABR, FACRO, highlights the importance of this milestone.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

PROSTOX ultra Reliably Predicts Long-Term Radiation AEs in Prostate Cancer

Roman Fabbricatore
April 9th 2025
Article

The phase 3 MIRAGE trial findings show that PROSTOX ultra was validated as a biomarker to predict genitourinary toxicity following SBRT.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.